Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.
about
Guanylate cyclase stimulators for pulmonary hypertensionRiociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Metabolic control of oocyte development: linking maternal nutrition and reproductive outcomesAbsorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)Stimulators of soluble guanylyl cyclase: future clinical indicationsRiociguat: first global approval.Riociguat for pulmonary hypertension.Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.Riociguat: a novel new drug for treatment of pulmonary hypertension.Riociguat for the treatment of pulmonary hypertension.Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 Inhibitor.Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorptionRiociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.Clinical implications of riociguat pharmacokinetics and pharmacodynamics: introduction to the riociguat clinical pharmacology supplement.Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.
P2860
Q26470534-FEFF2432-B9A4-4CF8-90E5-457117346FBEQ33596457-BCF1F4AA-836D-4E5D-A9E9-DBE0FB090011Q34416861-6DBAB595-2DA3-4C5F-B301-ECF8A2F6843BQ34444990-25C66F5F-5B40-4713-AD5E-988601653A60Q35010064-F4264971-B8B9-4B46-822B-374AFBE7AABDQ35075847-27438118-CEB0-4FAE-AD7E-6497951BF349Q35318639-F2784A8E-E807-4353-A3B2-3017B819523FQ36734217-153BFE63-9E36-4B41-9AED-238BCE683EF9Q36763080-99CC60E9-DD3B-4642-8B04-03C6A4E9623BQ36881722-17711B43-8F4C-411C-8AC0-C8373EC0BCEDQ38093420-9CA86EED-FFAD-4149-A457-A7FB78418E6BQ38161841-F5961F91-FB81-4D3F-A543-903D161BEE4AQ38192059-BCC323F6-3BAF-48E7-ADC5-0C57F79899ACQ38263468-8796985C-F2A8-48E2-A46D-C43B783E458EQ38502798-F2A4C497-A9AA-4B1F-817F-610622CE631FQ38645382-7E5FC6D6-3EAB-4E83-95B3-F6405E14C38AQ38893410-2D87EC88-535D-4A3F-8ADB-6DD58035D933Q41165804-F13D3546-E8F6-4FB6-988E-6997446B52DEQ41166010-B4670A95-0C82-49CA-BDE9-A098EB616AFDQ43119916-D5F87379-5E74-418A-AF5C-7044D67DFED9Q45723444-93A370B1-CBC5-4236-96A4-CCE5890F6EBAQ45906325-FD8AEAD7-684D-4FB0-B3C5-AC93132CDB68Q47584698-6E5C67EF-FE5F-4A77-8CA6-97F9DEEDF722
P2860
Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Riociguat (BAY 63-2521) and wa ...... macokinetic interaction study.
@ast
Riociguat (BAY 63-2521) and wa ...... macokinetic interaction study.
@en
type
label
Riociguat (BAY 63-2521) and wa ...... macokinetic interaction study.
@ast
Riociguat (BAY 63-2521) and wa ...... macokinetic interaction study.
@en
prefLabel
Riociguat (BAY 63-2521) and wa ...... macokinetic interaction study.
@ast
Riociguat (BAY 63-2521) and wa ...... macokinetic interaction study.
@en
P2093
P2860
P356
P1476
Riociguat (BAY 63-2521) and wa ...... macokinetic interaction study.
@en
P2093
Georg Wensing
Gerrit Weimann
Jörn Krätzschmar
Nina Kirschbaum
Reiner Frey
Wolfgang Mück
P2860
P304
P356
10.1177/0091270010378119
P577
2010-08-27T00:00:00Z